MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2017 International Congress

    Chorea and psychosis as stroke presentation : report and brief review

    F. RADJI (AGEN, France)

    Objective: Describe phenomenology of rare movement disorders in stroke presentation and it pathophysiology Background: Acute movement disorders are a rare presentation of ischaemic stroke. hemichorea…
  • 2017 International Congress

    Late-Onset Wilson’s disease, Dementia, Ekbom syndrome and whitte matter hyperintensities

    F. Germiniani, P. Marques, F. Zorzetto, L. de Oliveira, H. Teive (Curitiba, Brazil)

    Objective: The aim of this study is to describe a patient with late-onset Wilson’s disease, dementia and Ekbom Syndrome. Background: Wilson's disease is an autosomal-recessive disorder…
  • 2017 International Congress

    The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

    I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…
  • 2017 International Congress

    The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

    L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…
  • 2017 International Congress

    Capgras syndrome in advanced Parkinson disease

    C. Groth, A. Pusso, D. Huss, S. Sperling, B. Shah, M. Harrison, W.J. Elias, G.F. Wooten, M. Barrett (Charlottesville, VA, USA)

    Objective: The aims of this study were to investigate the frequency of Capgras syndrome in Parkinson's disease patients who have undergone Deep Brain Stimulation (DBS)…
  • 2017 International Congress

    Systematic Evaluation of Major and Minor Psychotic Symptoms in Parkinson’s Disease

    C. Kulick, K. Montgomery, M. Nirenberg (New York, NY, USA)

    Objective: To evaluate a structured clinical interview (SCI) based on the Parkinson’s disease-specific Scale for the Assessment of Positive Symptoms (SAPS-PD) in the identification of…
  • 2017 International Congress

    Baseline Clinical Predictors of Future Psychotic Symptoms in de novo Parkinson Disease

    M. Barrett, M. Smolkin (Charlottesville, VA, USA)

    Objective: To determine which baseline clinical symptoms are associated with future psychotic symptoms in de novo Parkinson disease (PD). Background: Because psychosis in PD is…
  • 2016 International Congress

    Factors related to psychotic symptoms in patients with Parkinson’s disease

    B. Tserensodnom (Ulaanbaatar, Mongolia)

    Objective: The aim of this study was to compare clinical characteristics in Parkinson's disease (PD) with psychosis (PDP) versus PD without psychosis (PDnP) and evaluate…
  • 2016 International Congress

    Categories of psychogenic movement disorders to functional blepharospasm

    J. Gazulla (Zaragoza, Spain)

    Objective: 1) To investigate if the categories of psychogenic dystonia (PD) proposed by Gupta and Lang could be applied to psychogenic blepharospasm (PB); 2) To…
  • 2016 International Congress

    Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy

    A. Tóth, H. Nagy, S. Funk, A. Takáts (Budapest, Hungary)

    Objective: Here we report the case of a 49-year-old man with a 19 years history of PD presenting DDS while he was on LCIG therapy.…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley